NLRP3 and familial dilated cardiomyopathy: (9) demonstrated that NLRP3 activation leads to the release of IL-1β and IL-18, which exacerbate myocardial fibrosis, oxidative damage, and disturbed energy metabolism; thus, targeting the NLRP3 inflammasome may serve as a therapeutic strategy for DCM.